Bernard Munos
Non-Executive Director
A senior fellow at FasterCures, a center of the Milken Institute, Bernard Munos advises organizations on being better innovators. Bernard is also the founder of the InnoThink Center for Research in Biomedical Innovation, a consultancy that helps biomedical research organizations become better innovators. Prior to that, he served as an advisor for corporate strategy at Eli Lilly, where he focused on disruptive innovation and the radical redesign of R&D. His research on pharmaceutical innovation has been published in Nature and Science, as well as profiled by Forbes magazine. In 2014, FiercePharma named him one of the 25 most influential people in biopharma. He previously served on the Advisory Council of the National Center for Advancing Translational Sciences (NCATS). Currently, he is a member of the National Academy of Medicine’s Forum on Drug R&D and Translation; the Advisory Board of the journal Science Translational Medicine; a non-executive director of Glenmark Pharmaceuticals; and an advisor to or board member of multiple companies and publicly financed research organizations. Bernard has discussed his research at numerous meetings sponsored by the President’s Cancer Panel, the National Institutes of Health Leadership Forum, the U.S. Food and Drug Administration, the World Health Organization, the Organization for Economic Cooperation and Development, the New York Academy of Sciences, the Brookings Institution, the Kauffman Foundation, the U.S. Patent and Trademark Office, and the American Chemical Society as well as at leading universities in the U.S., Europe, and Asia. He also blogs about innovation for Forbes and FasterCures. He received his master’s degree in business administration from Stanford University and holds other graduate degrees from the University of California at Davis and the Paris Institute of Technology for Life, Food and Environmental Sciences in France.
